Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zonisamide Versus Propranolol in Migraine
Sponsor: Kafrelsheikh University
Summary
Investigators aim to compare the effect of zonisamide versus propranolol in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency
Official title: Zonisamide Versus Propranolol in Migraine, a Randomized Controlled Single-blinded Trial
Key Details
Gender
All
Age Range
10 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2024-03-29
Completion Date
2025-04-20
Last Updated
2024-04-23
Healthy Volunteers
No
Conditions
Interventions
Zonisamide 50 MG
The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Propranolol
The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Locations (1)
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt